Fig. 8: Clinical validation and in vivo study of CTSH and PTGES3 functions. | npj Precision Oncology

Fig. 8: Clinical validation and in vivo study of CTSH and PTGES3 functions.

From: Integrating bulk, single-cell, and spatial transcriptomics to identify and functionally validate novel targets to enhance immunotherapy in NSCLC

Fig. 8

a Western blot was used to assess the expression of CTSH, PTGES3, RIPK3, and MLKL in normal and adjacent non-tumor tissues from patients with NSCLC. b–i The transcripts of these genes were measured with qRT-PCR (b–e), followed by correlation analysis (f–i). j Schematic diagram of the animal experiment design. Immune-competent wild-type C57BL/6 mice were subcutaneously injected with genetically manipulated Lewis lung carcinoma 1 (LLC1) cells to establish syngeneic mouse models of lung adenocarcinoma. k, l Representative tumors treated with Ctsh overexpression/shPtges3, mouse anti-PD-1 antibodies, and their combination. m, n Western blot analysis to measure necroptosis markers in tumors with the indicated treatment. o–r Weights (o, p) and volume growth curves (q, r) of LLC1 lung tumors. *P < 0.05, **P < 0.01, ***P < 0.001.

Back to article page